Sleep · Hypothalamic neuropeptide · Compounded 503A
DSIP: delta sleep-inducing peptide.
DSIP (delta sleep-inducing peptide) is a small endogenous neuropeptide first isolated from the cerebral venous blood of sleeping rabbits in the 1970s. It supports delta-wave (deep) sleep, modulates the stress axis, and is one of the few peptides clinically studied specifically for sleep architecture rather than sleep onset.
What DSIP is
DSIP is a nine-amino-acid neuropeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated by Schoenenberger and Monnier in 1977 from blood drawn from sleeping rabbits during a delta-EEG state.
It is endogenously present in the human hypothalamus, pituitary, and limbic system. Unlike sedative-hypnotics, it does not produce sleep onset by acting on the GABA-A benzodiazepine site — it supports the architecture of delta-wave sleep already underway.
It is investigational in the U.S. and dispensed through compounded pharmacy pathways for sleep architecture, stress modulation, and chronic-pain indications. Most peer-reviewed clinical work is European, particularly from the 1980s–90s.
How it works
DSIP modulates the HPA axis — reducing cortisol secretion and adrenergic tone — which lowers the physiological arousal that fragments sleep architecture.
It interacts with endogenous opioid and GABAergic systems, supporting the deep-sleep stages where growth hormone secretion and tissue repair are concentrated.
Unlike Z-drugs and benzodiazepines that produce sleep that is shallower on EEG, DSIP supports the slow-wave architecture associated with subjective restoration.
What patients use it for
Deep sleep architecture
DSIP supports delta-wave sleep — the stage where growth hormone secretion, glymphatic clearance, and tissue repair peak — without producing pharmacologically shallow sleep.
Stress and HPA modulation
By lowering cortisol and adrenergic tone, DSIP reduces the arousal-driven fragmentation of sleep common in chronic stress and perimenopause.
Chronic pain
European clinical work has investigated DSIP for chronic pain syndromes — leveraging both its sleep-architecture and direct analgesic effects through opioid system modulation.
Circadian normalization
DSIP has been studied for shift-work sleep disturbance and jet lag, where supporting deep-sleep architecture during off-cycle windows is the goal.
Evidence summary
Schoenenberger GA, Monnier M (PNAS, 1977) — the original isolation paper characterizing the delta-EEG sleep activity of the peptide that became DSIP.
Schneider-Helmert D (Sleep, 1985) reported clinical use of DSIP in chronic insomnia patients with improved sleep architecture metrics.
Larbig W et al. (European Neurology, 1984) investigated DSIP in chronic pain, demonstrating analgesic effect along with sleep architecture changes.
Honest framing: solid endogenous biology and meaningful European clinical literature from the 1980s–90s; limited modern Western RCT replication.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Most commonly subcutaneous injection, dosed in the evening before bed.
Course-based use (2–6 weeks) is more common than indefinite nightly use.
Compounded DSIP from licensed 503A pharmacies is the typical U.S. dispensing pathway. Not FDA-approved.
Safety and contraindications
Generally well-tolerated. The European clinical literature reports an unremarkable safety profile.
No reported dependence, tolerance, or withdrawal — a structural contrast with hypnotics.
Contraindications: pregnancy, lactation, known hypersensitivity. Use under physician supervision.
Who it's typically considered for
- Adults with fragmented sleep architecture or reduced slow-wave sleep on testing
- Perimenopausal patients with cortisol-driven sleep disturbance
- Patients seeking non-hypnotic, non-sedating sleep support
- Patients with chronic pain syndromes affecting sleep architecture
Frequently asked questions
Is DSIP a sleeping pill?
No. DSIP supports the architecture of sleep but does not produce sleep onset the way a hypnotic does. Patients who want immediate knock-out from a pill will be disappointed; those who want deeper, more restorative sleep are the right population.
Is DSIP FDA-approved?
No. DSIP is investigational; compounded preparations are dispensed by licensed 503A pharmacies under physician prescription for off-label use.
Will DSIP make me groggy in the morning?
Generally no — because it does not act on the GABA-A benzodiazepine site, it does not produce the morning sedation of Z-drugs or benzodiazepines.
DSIP vs melatonin?
Different roles. Melatonin signals 'it's nighttime' and supports sleep onset and circadian timing. DSIP supports the depth of sleep once you're in it. They are not alternatives — they address different aspects of sleep.
How quickly does DSIP work?
Effects on sleep architecture typically appear within 1–2 weeks of consistent dosing. Subjective sleep quality improvement varies by individual.
Can DSIP be used long-term?
Course-based use is more common than indefinite use. The European literature describes courses of weeks to a few months.
Is DSIP good for perimenopause sleep?
Perimenopause sleep disturbance often involves cortisol-driven fragmentation of deep sleep — exactly what DSIP's mechanism addresses. It's an option to discuss with your physician.
Sources
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. PNAS (1977). — pubmed.ncbi.nlm.nih.gov/16592405
- Schneider-Helmert D. Clinical evaluation of DSIP. Sleep (1985). — pubmed.ncbi.nlm.nih.gov/3936099
- Larbig W et al. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. European Neurology (1984). — pubmed.ncbi.nlm.nih.gov/6489364
Considering DSIP?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.